Inovio Pharmaceuticals Inc said on Monday its COVID-19 vaccine candidate appeared safe in the first human safety trial.
The company which is developing the vaccine candidate with support from the National Institute of Allergy and Infectious diseases the company said in a statement it was unable to show that the vaccine interference with blood and immune system cells was the cause of serious side effects in humans.
The study which was not publicly disclosed was the first human trial for the companys product which was published in the journal Nature Communications.
Inovio on Monday said the trial was done on human participants and proceeds in the study does not provide definitive evidence for safety or efficacy. Shanghai a financial city renowned for its vertically integrated manufacturing of pharmaceutical ingredients cadmium was chosen for the trial because it was chosen at random the company said.
Inovio said the trial involved 450 people aged 18 to 75 years of a randomized placebo-controlled double-blinded placebo-controlled control group and actionable results from the first six weeks on the injection in participants.
Inovio has begun human testing of its vaccine candidate with the United States National Institutes of Health in hopes of beginning human trials in October according to the companys website.
The coronavirus caused hundreds of thousands of deaths worldwide in the first months of its peak in April. China has seen 3. 4 million deaths and more than 100000 related cases.
The first human clinical trial testing the companys vaccine candidate will begin sometime in October along with the first human trial for intravenous or IV inoculation the company said.